Upgradation of Domestic Site to Regulatory

Upgrading a domestic pharmaceutical manufacturing site to regulatory standards means strengthening the facility, processes, documentation, quality systems, and manufacturing practices to meet applicable regulatory expectations. The exact requirements depend on the products manufactured, manufacturing activities, and target regulatory markets. For Indian pharmaceutical manufacturers, the applicable requirements may include Schedule M and other requirements issued by CDSCO and State Drug Control Authorities.

A domestic site may need to be upgraded when a company plans to meet higher GMP expectations, expand its product portfolio, supply regulated markets, or prepare for inspections by health authorities. Upgradation can involve improvements to facilities, utilities, equipment, documentation, quality systems, and manufacturing controls. The objective is to bring the site and its operations into alignment with the regulatory requirements applicable to its products and intended markets.

A regulatory site-upgradation assessment can cover facilities, utilities, production areas, warehouses, laboratories, equipment, personnel practices, documentation, quality management systems, validation, qualification, sanitation, environmental controls, data integrity, and material management. The review should be based on the regulations and regulatory expectations applicable to the site. A structured gap assessment helps identify which areas require modification, remediation, additional controls, or better documentation.

A GMP gap assessment is a systematic review that compares a manufacturing site’s current practices and systems with applicable Good Manufacturing Practice requirements. It can identify deficiencies in areas such as facility design, equipment, production controls, quality control, documentation, validation, training, and quality systems. The findings can then be prioritized according to their potential regulatory and product-quality impact, helping the company develop a practical remediation plan.

It can. Depending on the gaps identified and the applicable regulatory requirements, physical changes may be necessary. These could include modifications to manufacturing areas, material and personnel flows, storage facilities, utilities, HVAC systems, laboratory areas, equipment, or contamination-control measures. However, not every regulatory upgrade requires major construction. The appropriate changes should be determined through a documented assessment of the existing facility against the applicable GMP requirements.

Schedule M establishes Good Manufacturing Practices and requirements relating to premises, plant, equipment, and pharmaceutical manufacturing operations in India. Its requirements cover areas such as facilities, materials, production, quality control, documentation, and related manufacturing practices. Schedule M was revised in 2023, with implementation timelines subsequently specified for different categories of manufacturers. Companies should therefore assess their sites against the currently applicable requirements rather than relying on older versions of the regulation.

Preparation should begin with a detailed assessment of the site’s current compliance status. Companies can review facilities, utilities, equipment, procedures, records, training, validation, quality systems, data integrity, deviations, CAPA, change control, and other applicable GMP areas. A mock regulatory inspection can then be conducted to identify potential observations. Corrective actions should be documented, assigned to responsible teams, and followed through to effective implementation before the actual inspection.

In many cases, an existing facility can be upgraded through targeted improvements rather than complete reconstruction. The extent of work depends on the site’s existing design, manufacturing activities, product risks, utilities, equipment, and applicable regulatory requirements. A detailed gap assessment is useful for determining whether modifications, additional controls, equipment upgrades, layout changes, or improvements to quality systems are sufficient to address identified compliance gaps.

Documentation is an essential part of a regulatory site-upgradation project. Depending on the scope, this can include site and facility documents, SOPs, validation and qualification records, equipment documentation, training records, quality-system procedures, deviation and CAPA records, change controls, environmental monitoring records, and other GMP documentation. Documentation should accurately reflect actual operations. Regulators generally expect written procedures to be supported by evidence that those procedures are consistently implemented.

A GMP consultant can help evaluate the existing facility, identify regulatory gaps, prioritize remediation activities, and support implementation of corrective actions. Depending on the project scope, consulting support may include facility and GMP audits, quality-system review, SOP development, validation and qualification review, training, mock inspections, CAPA assessment, and regulatory inspection readiness. The consultant provides technical and compliance support, while the pharmaceutical company remains responsible for implementing and maintaining its regulatory obligations.